News

FREDERICK, Md. -- Nearly one-third of all human cancers are driven by mutations in RAS genes, including almost all pancreatic cancers. Treating these cancers has puzzled scientists for decades, and many RAS proteins are considered virtually undruggable. 

FREDERICK, Md. -- The Frederick National Laboratory for Cancer Research is opening potential new avenues for coaxing the human immune system to fight cancer and other diseases through microscopic particles, or nanoparticles.

The use of nanoparticles to transport drugs to cancer cells is a growing field that has piqued scientists’ interest over the last two decades. Nanoparticles show potential because they can directly target and treat cancer cells. 

FREDERICK, Md. -- The Frederick National Laboratory for Cancer Research will extend its scientific mentoring across international borders for the first time by offering postdoctoral research fellowships to scientists under an agreement with the National Cancer Institute of Mexico (INCan).

Under a three-year Memorandum of Understanding, the two institutions will cooperatively develop and launch a pilot program that will provide education and training in areas of mutual interest in cancer research.

FREDERICK, Md. -- Hundreds of science and business professionals are expected to attend the second annual Technology Showcase at the Frederick National Laboratory for Cancer Research, scheduled for June 13. 

The event will feature technologies being developed at the National Cancer Institute (NCI) and the Frederick National Laboratory to encourage startup company formation, technology licensing, and collaborations. 

FREDERICK, Md. -- Hood College and the Frederick National Laboratory for Cancer Research have partnered to cohost an annual scientific symposium in the tradition of the landmark Oncogene Meeting, a national fixture in Frederick for more than 20 years.

A recently signed, three-year Memorandum of Understanding between the two institutions also will expand research and training opportunities for undergraduate and graduate students at the Frederick National Laboratory and provide professional development programs for Hood faculty and national laboratory staff.

FREDERICK, Md. -- In early experiments, a targeted nanomedicine has safely halted the growth of pancreatic cancer — the deadliest of solid tumors — and prevented its most dangerous feature, metastasis, the spread of tumor cells.

SAN FRANCISCO – Computational drug design company Numerate has signed a letter of intent to join an open consortium of scientists staffed from two U.S. national laboratories, industry, and academia working to transform drug discovery and development into an approach that is rapid, integrated and with better patient outcomes.

FREDERICK, Md. -- A recent study that examined how mutations of a certain gene could affect clinical management of glioma, one of the most common types of primary brain tumors, is one of the first examples of the Genomic Data Commons’ impact on cancer research.